Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 3, 2014, Pages 476-485

  Müller, Cristina ^a   Reber, Josefine ^a   Haller, Stephanie ^a   Dorrer, Holger ^b,c   Bernhardt, Peter ^d,e   Zhernosekov, Konstantin ^b   Türler, Andreas ^b,c   Schibli, Roger ^a,f  

^a ETH Zurich   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f ETH ZURICH   (Switzerland)

Author keywords

161Tb; 177Lu; Cancer; Folate; Folate receptor; Therapy

Indexed keywords

ANIMALS; COORDINATION COMPLEXES; FEMALE; FOLIC ACID; HELA CELLS; HUMANS; LUTETIUM; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RADIOISOTOPES; RADIOPHARMACEUTICALS; TERBIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894067831     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2563-z     Document Type: Article

References (25)

1. Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011;18 Suppl 1:S27-51.
2. 3]octreotate. J Clin Oncol 2004;22:2724-9. (Pubitemid 41103761)
3. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47. (Pubitemid 29515605)
4. 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552-4.
5. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010;37:1018-31.
6. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22. (Pubitemid 36692868)
7. 3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
8. 3-octreotate. J Nucl Med 2005;46 Suppl 1:83S-91S. (Pubitemid 47619023)
9. 177Lu for targeted radionuclide therapy. Nucl Med Biol 2011;38:917-24.
10. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med 1995;22:608-16.
11. Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med 2012;53:1951-9.
12. Eckerman K, Endo A. ICRP Publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP 2008;38:7-96.
13. 177Lu-radionuclide tumor therapy in mice. J Nucl Med 2013;54:124-31.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
15. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 1996;37:1003-8. (Pubitemid 126447142)
16. Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 2007;67:6376-82. (Pubitemid 47037521)
17. Sanceau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002;21:7700-9. (Pubitemid 35398816)
18. Bernhardt P, Benjegård SA, Kölby L, Johanson V, Nilsson O, Ahlman H, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001;51:514-24. (Pubitemid 32884299)
19. 0]octreotide. J Nucl Med 2003;44:98-104. (Pubitemid 36077719)
20. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 2005;46:2097-103. (Pubitemid 46657459)
21. Uusijärvi H, Bernhardt P, Ericsson T, Forssell-Aronsson E. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution. Med Phys 2006;33:3260-9. (Pubitemid 44327428)
22. Forrer F, Valkema R, Bernard B, Schramm NU, Hoppin JW, Rolleman E, et al. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging 2006;33:1214-7. (Pubitemid 44484478)
23. 177Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109-18. (Pubitemid 37006325)
24. 177Lu nuclear reactions. Appl Radiat Isot 2008;66:1218-20.
25. 177Lu process. Appl Radiat Isotopes 2000;53:421-5. (Pubitemid 30320787)